| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(20 days from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
Fiasp Flextouch is owned by Novo.
Fiasp Flextouch contains Insulin Aspart.
Fiasp Flextouch has a total of 20 drug patents out of which 4 drug patents have expired.
Expired drug patents of Fiasp Flextouch are:
- US8672898
- US9486588
- US6899699
- US8579869
Fiasp Flextouch was authorised for market use on 29 September, 2017.
Fiasp Flextouch is available in solution;subcutaneous dosage forms.
The generics of Fiasp Flextouch are possible to be released after 01 February, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
FIASP FLEXTOUCH family patents
